The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (interstitial lung disease/ILD)

Publications

Pavlovi? M, Šeparovi? R, Silovski T, Te?i? Vuger A, Juri? A

OXALIPLATIN INDUCED PULMONARY FIBROSIS: A CASE REPORT.

Acta clinica Croatica 2020 Dec;59;761-764 — 2020 Dec — 761-764

Taooka Y, Yoke H, Inata J

Oxaliplatin-related interstitial pneumonia with high-grade fever and relative bradycardia as the presenting signs: a case report.

Journal of medical case reports 2021 Apr 08;15;153 — 2021 Apr 08 — 153

Suthar KH, Al Mutar S, Venkatesan R

Oxaliplatin-induced Pulmonary Toxicity: A Rare but Serious Complication.

Cureus 2020 Mar 31;12;e7483 — 2020 Mar 31 — e7483

De Weerdt A, Dendooven A, Snoeckx A, Pen J, Lammens M, Jorens PG

Prognosis and treatment of FOLFOX therapy related interstitial pneumonia: a plea for multimodal immune modulating therapy in the respiratory insufficient patient.

BMC cancer 2017 Aug 29;17;586 — 2017 Aug 29 — 586